Radiotherapy and zoledronic acid for the treatment of kidney cancer bone metastases

Radiotherapy is often used for the treatment of bone metastases from renal cell carcinoma (RCC). However, radiotherapy can cause a number of bone-related adverse events, such as fracture, loss of sensation and movement in the hands and feet (paraplegia), surgery or radiotherapy for local recurrence, or severe pain in bone metastases that  are resistant to […]

read more

Patterns of initial metastatic recurrence after surgery for high-risk kidney cancer patients

This study looked at where metastases occurred after surgery for high-risk non-metastatic renal cell carcinoma (RCC). The study also identified the factors that indicated outcomes for these patients. A total of 1,057 patients with stage T3a or greater RCC were treated with surgery. 160 patients (59.3%) had one site of initial metastatic recurrence, while 110 […]

read more

Bone metastases are associated with poor prognosis in papillary kidney cancer

A recent retrospective study looked at the data from 49 patients with metastatic papillary renal cell carcinoma (RCC) who were taking targeted therapy (VEGF-TKIs). The study showed that patients on targeted therapy and with bone metastases from papillary RCC have worse progression-free survival and overall survival than patients without bone metastasis. Patients with papillary RCC […]

read more

Bone-targeted therapies may improve survival in metastatic kidney cancer patients

A recent study published in the journal Translational Oncology suggests that bone-targeted therapies, such as denosumab and zoledronic acid may have a continued role in the treatment of patients with metastatic renal cell carcinoma (mRCC) in the era of targeted therapy and immunotherapy. Bone is the second most common site of metastasis in patients with […]

read more

Effect of treatment delay on outcomes in metastatic kidney cancer

A recent study published in Science Direct followed patients with metastatic renal cell carcinoma (RCC), who were ineligible for active surveillance, to determine whether a delay in receiving first-line treatment affected outcomes. In the study, the overall median treatment delay was 6.3 weeks. Patients with bone metastases and advanced disease at diagnosis were more likely […]

read more

Prognosis of kidney cancer with bone metastases

A recent study, published in the European Journal of Cancer, looked at the prognosis of metastatic renal cell carcinoma (RCC) patients with bone metastases treated at the Gustave Roussy Cancer Campus in France from 1992 to 2016. Of the 1750 patients diagnosed with RCC, 300 (17%) patients had bone metastases. Median overall survival for these […]

read more

Prognosis of kidney cancer patients with bone metastases

A recent study published in the European Journal of Cancer this month suggests that the Memorial Sloan-Kettering Cancer Center (MSKCC) risk score, the number of bone metastases, and surgical removal of bone metastases (radical resection) are important prognostic factors for patients with bone metastases from renal cell carcinoma (RCC). In addition, surgery to remove solitary […]

read more

Rise factors for bone cancer

A study involving 45,824 patients newly diagnosed with renal cell carcinoma (RCC), of which 1509 (3.29%) had bone metastases upon initial diagnosis, was recently reported in Cancer Management and Research. The researchers identified older age, male sex, lymph node involvement, and higher T stage among the risk factors for bone metastases at the initial diagnosis of RCC. The […]

read more

An interdisciplinary consensus on the management of bone metastases from renal cell carcinoma

The International Kidney Cancer Coalition (IKCC), of which KCSN is a member, together with the German Cancer Society working group on renal tumours convened a meeting of global experts to review current treatment strategies for bone metastases from renal cell carcinoma (RCC) with the aim to improve the management and outcomes of RCC patients. The […]

read more

Cabozantinib more effective than everolimus for treatment of kidney cancer bone metastases

Cabozantinib (Cabometyx) was more effective than everolimus (Afinitor) in people with advanced renal cell carcinoma (RCC) and bone metastases, according to a subgroup analysis of the METEOR clinical trial carried out by researchers at the Gustave Roussy Institute in Villejuif, France and published in Journal of Clinical Oncology. Progression-free survival in people with bone metastases was […]

read more
Showing 1 to 10 of 13 results
  TOP